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Introduction 
Cystic fibrosis (CF) is a single gene disorder with insufficient treatment options and a target 
organ, the lung, which is relatively easily accessible. Thus, gene therapy-based treatments 
may hold great promise for CF. The selection of appropriate gene transfer agents for chronic 
diseases such as CF, which require life-long treatment, is important. A variety of viral and 
non-viral vectors have been assessed in pre-clinical and clinical studies over the last 20 years 
since cloning the gene [1]. Although generally viral vectors are more efficient in transducing 
airway epithelial cells (the target cells in CF), than non-viral vectors, they (i.e adenovirus, 
adeno-associated virus and Sendai virus) invariably induce immune responses, which 
negatively impact on protein expression upon repeated administration [2] Interestingly, 
lentiviruses, which have recently been assessed for airway gene transfer, overcome this 
problem in pre-clinical studies [3,4], but have not yet been evaluated in clinical trials.  
 
A variety of non-viral vectors have been developed for airway gene transfer and assessed in 
clinical trials [1]. Although efficacy is generally lower than with virus-mediated gene 
transfer, proof-of-principle studies in both the nose [5-9] and the lung [10], as measured by 
vector-specific mRNA expression or partial correction of the CFTR-specific chloride 
transport defect, has been established in clinical trials. However, the level of correction of the 
CF defect necessary to produce meaningful clinical outcome is unknown. Thus, the UK 
Cystic Fibrosis Gene Therapy Consortium has initiated a clinical trial programme to assess 
whether repeated administrations of GL67A complexed to plasmid DNA encoding cystic 
fibrosis transmembrane conductance regulator (CFTR) cDNA can improve clinically relevant 
endpoints in the CF lung. Following extensive pre-clinical studies in mice [11] and sheep 
(manuscript submitted) the cationic lipid GL67A (Genzyme Corporation), which has already 
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been used in two previous CF gene therapy clinical studies [10, 12] was selected for this 
programme.  
 
Human air liquid interface (ALI) cultures are grown on semi-permeable membranes exposing 
the basolateral surface to growth medium and the apical surface to air and, when fully 
differentiated, have a cell composition similar to human airways [13,14]. ALI cultures remain 
viable for prolonged periods of time (months) and have been used for a variety of 
applications including investigation of respiratory pathogens [15] and toxicology studies 
[16,17]. However, similar to human airways, differentiated ALI cultures are relatively 
difficult to transfect, a feature which arguably makes them a particularly suitable model of 
human airways. The low transfection efficiency is likely due to a combination of factors 
including active mucociliary clearance due to cilia beating, mucus production and the fact 
that the cells are non-dividing. Despite these extra- and intra-cellular barriers several studies 
have shown that viral vectors are able to transduce fully-differentiated human ALI cultures 
[18-20].  In contrast, we and others have been unsuccessful in demonstrating recombinant 
protein expression in this model after non-viral gene transfer using a Firefly luciferase (FLuc) 
reporter gene (see data in this manuscript), which is generally regarded as a very sensitive 
reporter gene [21,22]. This represents a significant limitation in the development of these 
vectors for airway diseases such as CF. 
 
Recently, a  secreted luciferase reporter gene isolated from Gaussia princeps (GLuc) has 
been described [23]. The enzyme catalyzes the oxidation of the substrate coelenterazine 
leading to emission of light. GLuc is a secreted, thermostable and pH resistant protein [24]. In 
vitro studies have shown that GLuc is orders of magnitude more sensitive than Firefly or 
Renilla luciferase [23] and secreted alkaline phosphatase, a commonly used secreted reporter, 
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in mammalian cells [25,26]. GLuc has most commonly been used to study a variety of 
biological processes including quantification of tumour growth [27,23] and monitoring of 
microbial infections [28] as well as screens for small interference (si)RNA [29]. The GLuc 
reporter has not been extensively used in the context of non-viral gene transfer studies. 
Nakanishi et al injected a transposon carrying GLuc intravenously and documented sustained 
GLuc expression in blood for at least 2 months [30], but to the best of our knowledge there 
have not been any reports on using GLuc as a reporter for in vitro or in vivo gene transfer to 
airway epithelium. Here, we assessed if GLuc allows detection of GL67A-mediated gene 
transfer in fully differentiated human ALI cultures, as well as lungs of mouse and sheep. 
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Material and Methods 
Plasmids 
Plasmid pCMVGLuc1 expressing GLuc was purchased from Nanolights (Pinetop, Arizona, 
USA). Utilising a strategy described previously [31], the Firefly luciferase (FLuc) cDNA 
from plasmid pCIKFLuc, in which FLuc is expressed under the control of the human 
immediate/early cytomegalovirus (CMV) promoter/enhancer [31], was replaced with the 
GLuc cDNA from pCMVGLuc1 to generate the new plasmid, pCIKGLuc. A  CpG-depleted, 
codon-optimised version of the GLuc cDNA sequence was designed (soGLuc), and after 
synthesis (GENEART AG, Regensburg, Germany) was also used to replace the FLuc cDNA 
in pCIKFLuc to generate plasmid pCIKsoGLuc. Both pCIKGLuc and pCIKsoGLuc express 
an identical GLuc protein under the control of the CMV promoter/enhancer, with similar 
transfection efficiencies in 293T human embryonic kidney cells and ALIs (data not shown). 
Both plasmids were used in ALI experiments but only pCMVGLuc was used in in vivo 
studies. The soGLuc cDNA was also sub-cloned into a fourth generation, CpG-free plasmid 
backbone [32] under the control of the synthetic hCEFI promoter, (combining a CMV 
enhancer with a CpG-free version of the human elongation factor 1α promoter [32]) to 
generate plasmid pG4-hCEFIsoGLuc, (DNA manufactured by Cayla-InvivoGen, Toulouse, 
France). An “empty” plasmid (pCI) carrying no reporter gene was used as a negative control 
in some experiments. 
 
Gene transfer agents 
GL67A:  
The cationic lipid GL67A [33] consists of the cationic lipid GL67 [Cholest-5-en-3-ol (3β)-,3-
[(3-aminopropyl)[4-[(3-aminopropyl)amino]butyl]carbamate] (Genzyme Haverhill, UK), 
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DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and DMPE-PEG5000 (1,2-
Dimyristoyl-sn-Glycero-3-Phosphoethanolamine-N-[methoxy (Polyethyleneglycol)5000] 
(Avanti, Alabaster, Alabama, USA). To generate GL67A the three lipids are formulated at 
1:2:0.05 (GL67:DOPE:DMPE-PEG5000) molar ratios and freeze-dried by OctoPlus (Leiden, 
The Netherlands). Lipid:pDNA complexes for mouse nasal “sniffing” experiments were 
generated as previously described at 1:4 lipid:DNA molar ratio [33] containing 
approximately 0.8 mg pDNA/ml final formation. Lipid:pDNA complexes for ALI cultures 
and sheep nebulisation experiments were generated as previously described at 6:8 lipid:DNA 
molar ratio [32] containing approximately 2.65 mg pDNA/ml final formation; this 
formulation is similar to that used in previous clinical studies [10].  
 
cPEI:  
cPEI was prepared as described previously [34]. Briefly, complexes were prepared at a PEI 
nitrogen to DNA phosphate (N:P) molar ratio of 10:1 by slowly adding equal volumes of 
appropriately diluted aqueous pDNA to aqueous PEI (4.3 mg/ml, pH7.4) whilst vortexing, 
and allowing the mixture to stand at room temperature for 15-20 min to facilitate complex 
formation. Concentration of PEI/pDNA complexes was performed using a Model 8200 
stirred ultrafiltration cell (Millipore, Watford, UK) fitted with a regenerated cellulose filter 
with a nominal molecular weight limit (NMWL) of 100 kDa and operating under an applied 
pressure of 10 psi nitrogen gas. Concentration of material was performed using initial 
formulations prepared at 0.4 mg/ml.  A 90 ml volume at 0.4 mg/ml (36 mg) was concentrated 
until OD260 reading was equivalent to a concentration of 1.6 mg/ml +/- 10%. DNA 
concentration in the PEI/pDNA complexes was quantified by absorbance measurements at 
260 nm, using 1 OD260= 45 µg/ml for DNA bound to 25 kDa branched PEI [35].  
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Lipofectamine:  
Lipofectamine (LF) 2000 (Invitrogen, Paisley, UK), was complexed at a 2.5 µg LF2000: 1 µg 
pDNA ratio (w:w) according to manufacturer’s recommendation.  
 
Gene Transfer 
ALI:  
Fully differentiated human ALI cultures (MucilAir) were purchased from Epithelix SÀRL 
(Geneva, Switzerland) and cultured at 37°C and 5% CO2 in a humidified atmosphere in a 
standard tissue culture incubator according to manufacturer’s recommendation. The 
basolateral culture medium (MucilAir culture medium, Epithelix) was replaced every 2 to 3 
days. Appropriate quantities of lipid/pDNA complexes were diluted in 100 μl OptiMem/ALI. 
The complexes were removed 6 hr after transfection and the basolateral medium was 
replaced. At indicated time-points after transfection GLuc was collected from the apical 
surface by adding 100 μl MucilAir medium. After 1 h incubation at 37°C the ALI cultures 
were “washed” by gently pipetting the medium up and down five times. Preliminary 
experiments indicated that this procedure removed most of the GLuc from the apical surface 
(data not shown). The medium was then completely removed and stored at -80oC until further 
analysis. In some experiments basolateral medium was stored at -80oC to assess GLuc 
expression. Untransfected ALI cultures were included as negative controls. In preliminary 
experiments we determined that background luciferase expression was identical in 
untransfected ALIs and ALIs transfected with pCIKempty (data not shown). 
 
For quantification of intracellular FLuc cell lysates were prepared by adding 100 µl and 500 
µl reporter gene lysis buffer (RLB, Roche, Basel, Switzerland) to the apical and basolateral 
surface of the ALI cultures, respectively. ALI cultures were incubated at room temperature 
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(RT) for 20 min and cells were scraped off the membrane using a pipette tip. Cells were then 
freeze/thawed three times to ensure complete lysis and spun at 13,000 gav at 4°C for 10 min. 
The supernatant was frozen for analysis.  
 
 Mouse:  
All animal studies had been approved by local Animal Ethics Committees at Imperial College 
and Edinburgh University and were carried out according to Home Office regulations. 
Female Balb/C mice (8-10 weeks old) (Charles River Laboratories, Wilmington, Germany) 
were used. For administration of the gene transfer agent by nasal “sniffing” animals were 
anaesthetized with isoflurane and 100 μl of lipid:pDNA complexes containing 80 μg of 
pDNA were administered to the nostrils and “sniffed” into the lungs as previously described 
[36]. At indicated time-points after instillation mice were culled. Blood was collected by 
cardiac puncture of the left ventricle, incubated at 37°C for 1 h and centrifuged at 3,000 gav 
for 10 min to prepare serum which was stored at -80oC until further analysis. Broncho-
alveolar lavage fluid (BALF) was collected by inserting a 22G venflon catheter (Abbocath, 
Sligo, Ireland) into the trachea. 0.5 ml of PBS (pH7.8, Sigma-Aldrich, Gillingham, UK) was 
then injected gently with a syringe and withdrawn; the procedure was repeated three times 
(3x0.5 ml PBS). BALF was then centrifuged at 5,000 gav for 20 min. The supernatant was 
collected and stored at -80oC until further analysis. Lungs were harvested and snap-frozen in 
liquid nitrogen and subsequently homogenised in 300 μl of RLB using a Fast-Prep 
homogenizer (ThermoFisher Scientific, Waltham, USA) at 4.0 m/s for 45s. After vortexing 
and incubation at room temperature for 15 min, the homogenate was transferred to a 
Qiashredder column (Qiagen, Crawley, UK) and centrifuged at 13,000 gav for 1 min. 
Columns were then removed and the homogenate was centrifuged for an additional 5 min. 
The supernatant was collected and stored at -80oC until further analysis. 
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Sheep: 
 Suffolk Cross ewes, 35-60 kg, were treated with anthelminthic (5% Fasinex, 1 ml/kg, 
(Novartis Animal Health, Camberley, UK), 1% Cydectin, 0.02 ml/kg, (Fort Dodge Animal 
Health, Southampton, UK)) and underwent a preliminary examination involving peripheral 
blood sampling and bronchoscopic visualisation and recovery of BALF under gaseous 
anaesthesia on a positive pressure ventilation system (Model 708, Harvard Apparatus, 
Holliston, MA), 1 to 3 weeks prior to treatment, to confirm absence of pre-existing 
pulmonary disease. Aliquots of serum were stored at -80oC as pre-treatment controls. Pre-
treatment BALF was collected by bronchoscopy from the right apical lung segment of some 
animals by instillation and recovery of 2×20 ml of sterile PBS pH 7.8. In addition BALF 
from untreated control animals was collected by instillation and recovery of 2×20 ml of 
sterile PBS pH 7.4. Control BALF at pH 7.8 had slightly higher background light emission 
than BALF collected with PBS at pH 7.4 (pH 7.8: 131.8±8.1, pH 7.4: 101.3±2.0 RLU/μl, 
p<0.05), but this small difference did not affect interpretation of the data. BALF was filtered 
through gauze to remove mucus and large particulates and stored at -80oC until further 
analysis. 
20 ml of pDNA complexed to either GL67A or PEI containing approximately 53 mg and 32 
mg pDNA, respectively were delivered as an aerosol to anesthetised sheep using PARI LC 
Plus nebulisers as previously described [34,37]. Twenty four hours after gene delivery a 
peripheral blood sample was taken. Sheep were euthanised and lungs removed and dissected 
free from surrounding tissue. Pulmonary circulation was perfused with 2-3L of PBS (pH7.8) 
to minimise haemoglobin content of samples. BAL samples were collected by single 
instillation and recovery of 40 ml of PBS (pH 7.8)/segment. BAL fluid was filtered through 
gauze to remove mucous and large particulates, stored on ice and then centrifuged for 20 min 
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at 5,000rpm. Biopsies were taken from airway bifurcations of eight lung segments using 
Gerritsma nasal biopsy forceps and stored at -80°C. Biopsies were then allowed to thaw and 
homogenised by hand using microscissors for 1 min in 150μl of RLB. Samples were freeze-
thawed three times (homogenising at each thaw with microscissors) followed by 5 min 
centrifugation at 3,000 rpm. Bronchial brushings (BBr)), were obtained from airway 
bifurcations using interdental brushes (Number 620, Dent-O-Care, London, UK) and 
harvested either into 1 ml PBS and pelleted for GLuc assay. Cell pellets were processed 
similarly to biopsies, but in 100 μl of RLB, and without microscissors homogenisation after 
first thaw. Tissue pieces were obtained as described previously [37] and homogenised in 400 
μl of 1xRLB as described for mouse lung, with an additional homogenisation cycle.  
 
Spiking experiments 
To determine the half-life of recombinant FLuc and GLuc proteins in apical fluid collected 
from ALI cultures 100 μl MucilAir culture medium were added to untransfected cultures 
(n=6). After 30 min incubation at 37oC the ALI cultures were “washed” by gently pipetting 
the PBS up and down 3 times. The liquid was collected and pooled. The apical liquid was 
spiked with known amounts of recombinant FLuc (Promega) and GLuc (Nanolight, Pinetop, 
AZ, USA) protein and samples were analysed for protein levels in an Appliskan plate reader 
(ThermoFisher Scientific, Waltham, MA, USA) immediately after spiking (T0) and at 
indicated time-points (up to 5 days) after storage at 37oC, 5% CO2.  
 
Assays 
Histological processing of ALI cultures:  
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Cells were fixed in osmium tetroxide (OsO4)-based fixative and embedded in araldite as 
previously described [38]. The araldite blocks were trimmed and semi-thin sections (1 μm) 
were cut (n=12 ALIs, n=6 levels/ALI. at approximately 300 μm intervals). The sections were 
stained with toluidine blue using standard histological techniques. Light microscopic analysis 
was performed using a Zeiss Axioskop 2 Plus microscope and 100x oil objective (Carl Zeiss 
Ltd, Welwyn Garden City, UK). Images were taken using Axiovision software (Axioskop 2 
plus).  
 
Electrical assessment of ALI cultures in Ussing chambers:  
ALI cultures were mounted in an Ussing chamber (Warner Instruments Hamden, CT, USA, 
dual chamber model U2500) according to manufacturer’s instructions 
(http://www.warneronline.com/Documents/uploader/U-2500%20%20(1999.07.07).pdf). The 
cells were maintained at 37oC and gassed with 95%/5% oxygen/CO2 in Krebs-Henseleit 
buffer (NaHCO3 24.8 mM, NaCl 118 mM, KCl 4.8 mM, MgSO4.7H20 1.8 mM, KH2PO4 
0.92mM, CaCl2.6H20 2.74 mM). After stabilisation for 15 min the buffer resistance was 
dialled-out with a DVC-1000 epithelial dual voltage clamp and short circuit current 
measurements were performed. After determining the baseline current, sodium absorption via 
epithelial sodium channels (ENaC) was inhibited through addition of 10 μM amiloride 
(Sigma, Gillingham, UK) to the mucosal surface. Subsequently forskolin (1 μM in ethanol, 
Sigma, Gillingham, UK) was added to the mucosal and serosal surface to increase 
intracellular cAMP concentration and activate CFTR-dependent chloride secretion. All data 
was stored graphically via Chart software after analogue to digital conversion (AD 
Instruments, Lawrenceville, GA, USA). 
Firefly luciferase (FLuc):  
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FLuc bioluminescence was measured using a Firefly Luciferase Assay Kit (Promega, 
Southampton, UK) according to manufacturer’s recommendation using an Appliskan plate 
reader (ThermoFisher Scientific, Waltham, MA, USA). Total protein was determined using a 
Bio-Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA) according to manufacturer’s 
recommendation and the data were expressed as relative light units (RLU)/mg total protein.  
Gaussia luciferase (GLuc):  
GLuc assays were performed using a Gaussia Luciferase Assay Kit (New England Biolabs, 
Ipswich, USA) according to manufacturer’s recommendation and an Appliskan plate reader. 
For lung tissue homogenates total protein was determined using a Bio-Rad DC Protein Assay 
Kit (Bio-Rad, Hercules, CA, USA) according to manufacturer’s recommendation and the data 
was expressed as RLU/mg total protein. For ALI cultures, serum and BALF samples, GLuc 
expression was expressed as RLU/μl fluid. 
Bioluminescent imaging: 
 D-Luciferin (75 mg/kg in 100 μl, Xenogen Corporation, Alameda, CA) or coelenterazine 
[first dissolved in methanol (4 mg/ml) and then diluted to 0.67 mg/ml in PBS; a 150 μl were 
delivered per mouse, Nanolight Technology, Pinetop, AZ, USA] was administered topically 
using our “nasal sniffing” protocol described above, to mice 10 min before imaging. 
Bioluminescence (photons s-1 cm-2 sr-1) from living mice was measured using an IVIS50 
system (Xenogen Corporation, Alameda, CA, USA) at a binning of 4, over 10 minutes, using 
the software programme Living Image (Xenogen). For anatomical localisation a 
pseudocolour image representing light intensity (blue least intense, red most intense) was 
generated using Living Image software and superimposed over the greyscale reference image. 
To quantify bioluminescence in the lungs photon emission in the lung was measured by 
marking a standardized area for quantification.  
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RT-PCR assays:  
For RNA analysis, cells were scraped into 350µl RLT/βME and extracts passed through a 
Qiashredder (Qiagen). Total RNA was extracted from cleared cell lysates using RNeasy 
columns (Qiagen) with on-column DNase treatment (Qiagen) and in-solution DNase 
(Ambion DNAfree), according to manufacturers’ instructions. Absolute levels of mRNA 
were quantified by two-step, real-time quantitative TaqMan RT-PCR using the ABI PRISM 
7700 Sequence Detection System and Sequence Detector v1.6.3 software (Applied 
Biosystems, Warrington, Cheshire, UK), using plasmid or endogenous mRNA-specific 
primers and fluorogenic probes, on undiluted RNA. Sequences of the forward (F), reverse 
(R), probe (P) and reverse transcriptase reaction priming (R2) oligonucleotides used for each 
mRNA target are listed below. Where no R2 oligonucleotide is indicated, the R primer was 
utilised in reverse transcriptase reactions. For pCIKFLuc (also known as pCIKLux), F: 5’-
TGA GGC ACT GGG CAG GTG T-3’, R: 5’-GTC GTA TTA AGT ACT CTA GCC TTA 
AGA-3’, P: 5’-FAM-CCA CTC CCA GTT CAA TTA CAG C-TAMRA-3’, R2: 5’-GCT 
CGT CGT ATT AAG TAC TCT AGC-3’; for endogenous human CFTR, F: 5’-GGA AAA 
GGC CAG CGT TGT C-3’, R: 5’-CCA GGC GCT GTC TGT ATC CT-3’, P: 5’-FAM-CCA 
AAC TTT TTT TCA GCT GGA CCA GAC CAA-TAMRA-3’; for endogenous ovine CFTR, 
F: 5’-GGA AAA GGC CAG CGT CGT C-3’, R: 5’-CCA AGC GCT GTC TGT ATC CT-3’, 
P: 5’-FAM-CCA AAC TTT TTT TCA GCT GGA CCA GAC CAA-TAMRA-3’, 
respectively. A 'no template control' and a 'no-reverse transcriptase' (RT-) control were 
included, where total RNA, or MultiScribe reverse transcriptase and RNase inhibitor were 
omitted from the reverse transcriptase reaction, respectively. 
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The number of copies of plasmid-derived mRNA and endogenous mRNA were calculated 
from standard curves of in vitro transcribed RNA fragments that surrounded the amplified 
region as previously described [39]. The amount of plasmid-derived mRNA was expressed as 
a percentage of the endogenous mRNA detected, such that samples containing equivalent 
amounts of each mRNA are expressed as 100% vector/endogenous mRNA. Samples for 
which the RT- reaction was within 3 Ct of the mean RT+ Ct value are reported as 'Not 
Determined'. Samples with quantifiable vector mRNA, and with endogenous mRNA levels 
below the lowest standard, are reported as 'Positive But Not Quantifiable'. Samples with 
vector mRNA copy numbers between 0 and the lowest standard are reported as ‘Positive But 
Not Quantifiable’. If no vector copies are detected and endogenous mRNA is quantifiable, 
samples are reported as 'No Vector Detected', otherwise they are reported as ‘Not 
Determined’. 
Statistics 
To assess normal distribution of the data the Kolmogorov-Smirnov normality test was 
performed. 2-group comparison of parametric data was performed using independent student 
t-tests (Figs. 5 and 8a) and paired t-test (Fig 9), as appropriate. Non-parametric data were 
analysed using a Kruskal-Wallis test followed by Dunns-multiple-comparison post-hoc test 
(Figs 2 and 3) or Mann-Whitney (Figs 1, 6, 7 and 8b) as appropriate. The Spearman R 
correlation coefficient was used to analyse non-parametric data. All analysis was performed 
using GraphPad Prism4 and in all cases the null hypothesis was rejected at p<0.05. 
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Results 
Histological and electrical assessment of ALI  cultures  
To confirm that commercially available MucilAir human ALIs were of suitable quality to be 
used as a model for airway gene transfer we assessed the cultures histologically and measured 
their ion transport properties in Ussing chambers. Fully differentiated ALIs exhibited a 
pseudostratified epithelium of ciliated, mucus and basal cells that is indistinguishable from 
native human airways (Figure 1A, image representative of n=12 ALIs). Further, the ALIs 
expressed endogenous human CFTR mRNA (123 ±25 copies/ng total RNA, n=16, two ALI 
batches assessed in independent experiments). Finally, their ion transport properties were 
similar to native human airways, with cultures responding to amiloride (reduction in potential 
difference (PD) due to inhibition of amiloride-sensitive sodium channels) and to perfusion 
with a low chloride solution containing forskolin which activates the cAMP-dependent CFTR 
chloride channel leading to hyperpolarisation across airway epithelium (Figure 1B, trace 
representative of n=8 ALIs).  
 
Non-viral gene transfer into ALI cultures  
Historically, others and we have struggled to detect robust levels of FLuc expression after 
non-viral gene transfer in ALIs. Transfection of ALIs with pCIKFLuc complexed to GL67A 
(10 μg DNA/ALI) resulted only in a 1.6-fold increased in FLuc expression compared to 
controls (n=12 ALIs/group, 2 independent experiments, p<0.05) when assayed 48 hrs post- 
transfection (Figure 1C). In contrast transfection with pCIKGLuc complexed to GL67A (10 
μg DNA/ALI) resulted in a 10-fold increase in GLuc expression compared to controls (n=6-
12/group, two independent experiments, p<0.001) when performed side-by-side with the 
same batch of ALIs (Figure 1D). Quantification of vector-specific mRNA 48 hrs after 
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transfection, showed that similar levels of  pCIKFLuc and pCIKGLuc mRNA were produced 
(Figure 1E, n=6/group), implying that the difference was related to the sensitivity of the 
assay as opposed differences in transfection efficiency. To address this point further we 
spiked apical ALI fluid with FLuc or GLuc protein and assessed decay over time. After a 2 h 
incubation only 5% of the FLuc activity was still detectable, whereas GLuc activity was still 
evident with 96% and 46% of protein activity remaining after 2 and 120 hr, respectively. The 
increased stability of the GLuc protein likely contributed to the enhanced sensitivity of this 
reporter and, importantly, confirmed that the cationic lipid GL67A, which is currently used in 
CF clinical  trials, transfects differentiated human airway epithelial cells. GLuc activity was 
also detectable in the basolateral medium after non-viral gene transfer and there was a 
significant correlation (r2= 0.7729, p<0.0001, n=82 samples) between gene expression in the 
apical and basolateral compartments. For this reason, only GLuc levels in the apical 
compartments  were quantified for subsequent experiments. 
 
Variable gene transfer into ALI cultures  
During the course of our studies we noticed significant variability in transfection efficiency 
when performing independent experiments. We hypothesised that the age of the ALIs may 
contribute to the observed variability. Figure 2A and B shows transfection efficiency of 
GL67A and LF2000 as a function of ALI age. These data imply that older ALIs are more 
refractory to transfection. To address this point further we compared the transfection activity 
of GL67A:pCMV-GLuc complexes in younger (<80 days, n=4) and older cultures (>120 
days, n=4) (Figure 2C) and showed that GLuc levels were higher in younger than older 
cultures (p<0.01). Subsequent experiments, therefore, were performed on cultures that were 
40 to 70 days post-seeding.  
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GLuc protein detection and  RT-PCR 
Identifying the most sensitive assay to measure the transfection activit of non-viral gene 
transfer vectors in ALI cultures is important. Real-time quantitative RT-PCR is generally 
regarded as a very sensitive assay for the detection of vector-specific mRNA. Here, we 
compared the relative sensitivities of assays to measure GLuc protein and mRNA levels. ALI 
cultures were transfected with varying amounts of pCIKsoGluc complexed to GL67A (0.1, 1 
and 10 μg DNA/ALI) and GLuc and mRNA levels were quantified in the same ALI cultures. 
As shown in Figure 3A and B robust levels of GLuc protein (p<0.005, n=6/group) and 
mRNA (p<0.01, n=6/group), could be detected in ALI cultures transfected with 10 μg DNA 
but not in ALIs transfected with lower amounts of plasmid DNA. We, therefore, concluded 
that the sensitivity of assays to detect GLuc protein and mRNA levels are similar, but 
importantly GLuc can be repeatedly quantified in the same ALIs whereas mRNA 
quantification is a terminal endpoint.  
 
Assessment of promoter activity in  human ALI cultures  
We recently developed a synthetic, hybrid promoter (hCEFI), combining a CMV enhancer 
with a CpG-free version of the human elongation factor 1α promoter (hCEFI) which shows 
persistent expression in mouse lung [32] and is currently being used in our CF gene therapy 
trial. The ability to measure GLuc in transfected human ALI cultures provides us with a tool 
to assess the activity of this promoter in a human airway model. Figure 4 shows that the 
hCEFI promoter in plasmid pG4-hCEFIsoGLuc can support persistent expression for at least 
1 month (p<0.05 when compared to negative control or pCIKGLuc, n=6/group), whereas the 
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CMV promoter, consistent with published in vivo data, is shorter-acting with high levels of 
expression detected within 48 hr of transfection followed by a rapid decline to baseline levels 
by day 8 after transfection. 
 
GLuc expression in mouse lung tissue, BALF and serum  
We have successfully used FLuc for many years to quantify GL67A-mediated gene transfer 
in the murine lungs in vivo. However, in our in vivo sheep model FLuc expression was not 
detectable (data not shown), despite robust levels of mRNA expression (McLachlan, 
manuscript submitted). Given the improved sensitivity of GLuc in ALIs we wished to assess 
this reporter in the sheep lung. However, before embarking on expensive large animal 
studies, we first assessed if GLuc was a robust reporter of non-viral gene transfer in mice.  
pCMV-GLuc/GL67A was administered to mice by nasal sniffing and GLuc expression was 
quantified in lung homogenate, BALF and serum 24 hr after transfection. Robust levels of 
GLuc expression (p<0.01 compared to negative controls, n=5-6/group) were detectable in 
lung homogenate, BALF and serum (Figure 5A-C), indicating that GLuc is a suitable 
reporter for the assessment of lung gene transfer. These results were reproduced in an 
independent experiment and although absolute levels of gene expression were lower (data not 
shown) there was good correlation between gene expression in lung homogenate and BALF 
(r2=0.84, p<0.005).  
We previously showed that non-viral mediated expression of FLuc expression in the lung can 
be detected using bioluminescence in vivo imaging (BLI) [40]. We, therefore, also assessed if 
BLI is suitable for detecting GLuc expression. Figure 6A-C shows that although GLuc can 
be detected in the lung, administration of the substrate coelenterazine to the airways leads to 
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significant levels of background light emission in untreated control animal, which was seen 
after luciferin administration [40]. Thus, whilst GLuc is a sensitive reporter gene for non-
viral lung transfection in mice, we caution against the use of GLuc for in vivo BLI after 
topical administration of its substrate coelenterazine.  
 
GLuc protein expression in sheep lung  
Sheep were nebulised with pCIKGLuc complexed to GL67A and GLuc expression quantified 
in lung tissue 24 h after transfection. Significant (p<0.005) levels of GLuc were readily 
detectable in lung [11- fold over untransfected controls (n=6/group)] (Figure 7A) indicating 
successful GL67A-mediated protein expression in a large animal. 
Detection of GLuc in lung tissue homogenate is a post-mortem procedure that does not easily 
lend itself to monitoring duration of gene expression over time. We, therefore, also assessed 
GLuc expression in BALF, bronchial biopsies (BBx) and bronchial brushings (BBr) that can 
be repeatedly collected from anaesthetised sheep. Significant (p<0.0001) levels of GLuc were 
detectable in BALF [9-fold over untransfected controls (n=6/group)] (Figure 7B) but not in 
BBx and BBr. In addition, there was a significant correlation between GLuc levels in tissue 
homogenate and BALF (Spearman r= 0.62, p<0.01). Thus, analysis of BALF may allow for 
monitoring of gene expression in the lung over time. 
 
GLuc expression in sheep serum 
Although BALF can be collected repeatedly in sheep to monitor the duration of gene 
expression, the procedure requires the sheep to be anaesthetised. In contrast collection of 
blood can be undertaken without anaesthesia; we, therefore, also assessed if GLuc can be 
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detected in serum. However, we were unable to detect significant increases in GLuc 
expression 24 h after GL67A/pCIKGLuc transfection (pre-treatment: 1469±179 RLU/μl 
serum, post-treatment: 1755±243 RLU/μl serum, n=9).  
Since our mouse experiments indicated that detection of GLuc in serum was feasible if gene 
transfer in the lung is sufficiently high, we delivered pCIKGLuc in a concentrated PEI  
(cPEI) formulation which we previously showed is capable of mediating robust levels of 
Firefly luciferase expression in the sheep lung [41]. cPEI-mediated gene transfer increased 
GLuc expression significantly by approximately 2 to 3-fold compared to GL67A-mediated 
expression (Figure 8A+B), which  led to a small but significant (p<0.05) increase in serum 
GLuc levels (Figure 8C).   
 
GLuc expression profile in sheep lung 
Although GLuc expression in BALF may be suitable to determine duration of gene 
expression after non-viral gene transfer in sheep, we were concerned that the expression 
profile may be affected by the enhanced stability of GLuc that we and others observed in ex 
vivo models (see above). To address this point we collected BALF 1, 4, 7, 14 and 21 days 
following aerosol delivery to sheep with GL67A/pCIKGLuc (n=3). The expression profile 
mimicked the predicted activity of the short-acting CMV promoter, with high levels of GLuc 
expression 24 h after transfection returning to baseline levels by day 4 (Figure 9). Thus, 
GLuc is a suitable reporter gene to follow gene expression in the sheep lung. In addition, this 
experiment showed that GL67A-mediated GLuc expression levels 24 h after gene transfer to 
the ovine lung was reproducible in independent experiments (compare levels in Figures 8a 
and 9), further supporting GL67A as a robust transfection agent in large animals.  
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Discussion 
Gene transfer agents are frequently assessed in ‘easy-to-transfect’ cell lines, potentially 
leading to over-expectations as to their performance in an in vivo setting. It seems more 
logical to test these agents in model systems that more closely mimic the clinical setting for 
which they are often intended for. Here we generated data that suggests that human ALIs may 
provide a more appropriate in vitro model, more akin to the situation in vivo. We provide 
evidence to suggest that the difficulty of previous efforts to score transfection activity of non-
viral vectors was likely related to the sensitivity of the reporter gene. Gaussia-derived 
luciferase provides significantly increased sensitivity via reduced protein breakdown as well 
as higher quantum yield and being secreted allows for assessment of gene transfer at multiple 
time-points in the same tissue or animal. We suggest this reporter gene deserves 
consideration as the standard for gene transfer studies to the respiratory epithelium. 
Assessment of the histological and ion transport properties of the commercially available ALI 
cultures showed they closely resembled normal human airway epithelium. The ALI cultures 
consisted of a pseudostratified epithelium composed of ciliated, mucus and basal cells  
similar to reported by Wiszniewski et al [13]. In addition the cultures were electrically tight 
and displayed ion transport properties characteristic of non-CF airway epithelium [13], 
including forskolin-mediated chloride secretion via cAMP-dependent chloride channels. 
MucilAir ALI cultures were, therefore, considered a suitable model for human airways. 
Significant inter-experimental variability in gene expression remains a problem for 
transfection of the MucilAir human ALI cultures. The cause is not completely understood, 
but our data indicate that the age of cultures, rather than donor variability, may in part 
determine transfection efficiency. We hypothesise that the generally lower transfection 
efficiency observed in older cultures, may relate to an increase in the volume of the mucus 
barrier, which accumulates over time. We now perform all our experiments in 40 to 70 day 
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old cultures. Cultures younger than 40 days may not always be fully differentiated (Epithelix, 
personal communication, March 2008) and are, therefore, less useful.  
 
Both the pCIKGLuc and pCIKFLuc expression plasmids carry a CMV promoter/enhancer 
and are, except for the reporter gene, identical. Thus, it is unsurprising that vector-specific 
mRNA levels after GL67A-mediated gene transfer were similar. Despite this finding, FLuc 
protein expression was barely detectable whereas secreted GLuc on the apical surface of 
ALIs was approximately 10-fold greater than in controls. We speculated that the increased 
signal-to-noise ratio of GLuc might be due to the increased stability of the protein in the 
context of airway surface liquid. Although apical liquid from ALIs was collected by washing 
the surface of the cultures with medium, which led to dilution of the airway surface liquid 
and proteases therein, the data showed that FLuc activity, consistent with previous reports, 
decreased rapidly [42]. In contrast the GLuc activity, consistent with published stability data 
(6 day half-life at 4oC [24]) was maintained for prolonged periods of time (46% after 120 hrs 
at 37oC), likely leading to accumulation of the protein over time. In addition to the prolonged 
half-life, the higher quantum yield, defined as the probability of photon emission per 
substrate molecule, of GLuc compared to FLuc contributes to the increased sensitivity of this 
assay. Consistent with our data, Tannous et al have previously shown that GLuc plasmids 
produces more than 1000-fold higher bioluminescence compared to FLuc plasmids after non-
viral transfection of 293T cells [23]. 
 
In addition to the apical surface GLuc was also detectable in the basolateral medium and the 
relative concentrations in the two compartments correlated well. It is unclear if the 
comparatively small protein (19.9 kD) was secreted via the basolateral membrane or moved 
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from the apical surface to the basolateral side via paracellular routes. Importantly, sampling 
the basolateral medium of ALI cultures avoids the need for “washing” and, therefore, 
perturbing the apical surface and may be more suitable to follow gene expression in ALIs 
over time.    
Despite its prolonged half-life, GLuc is suitable to assess promoter activity in human ALIs 
over-time. “Washing” of the apical surface with medium removes most of the accumulated 
GLuc and, thereby, allows accurate quantification of newly produced GLuc at later time-
points. In addition quantification of GLuc in the basolateral medium, which can be 
completely removed and changed, is a suitable way to follow gene expression over time. A 
comparison of CMV- and hCEFI-mediated GLuc expression not only showed that the hybrid 
hCEFI promoter/enhancer supports long lasting expression in a human airway model 
compared to the CMV promoter/enhancer, but also demonstrated that human ALIs mimic the 
in vivo performance of these regulatory elements in mouse models [32]. Studies in human 
ALIs may, therefore, be useful to assess promoter function and duration of expression in the 
context of human cells. 
GL67A-mediated CFTR gene transfer into lungs of CF patients has been shown to partially 
correct the CF chloride transport defect [10]. In addition, we can detect robust levels of 
vector-specific mRNA (copy number equivalent to approximately 50% of ovine CFTR 
mRNA, median from n= 8 sheep, manuscript submitted) in lung tissue. However, we have 
not been able to detect expression of FLuc at these levels of gene transfer (data not shown). 
Here, we assessed if GLuc offers advantages over FLuc in detecting gene expression in the 
sheep lung. However, before embarking on studies in large animals models we assessed if 
GLuc is a suitable reporter gene for non-viral lung transfections in mice. Encouragingly we 
were able to detect robust levels of GLuc not only in lung homogenate, but also in BALF and 
serum of treated mice. In pre-clinical and clinical CF gene therapy studies we, and others, 
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often rely on detection of vector-specific mRNA by quantitative RT-PCR, generally regarded 
as a very sensitive assay, to provide evidence of successful gene transfer. Interestingly, the 
relative sensitivity of GLuc and QRT-PCR were comparable. In other studies, we are 
beginning to accumulate data suggesting that CFTR protein function may be a more sensitive 
assay than RT-PCR mRNA detection (manuscript in preparation). Thus, we question whether 
the latter should be considered the gold standard for molecular detection of gene transfer, 
where alternative means exist.   
We have previously shown that FLuc expression after non-viral gene transfer to the lung can 
be detected using bioluminescence in vivo imaging (BLI) [43] and have also shown that 
photon emission is enhanced if the substrate luciferin is delivered topically by nasal 
instillation rather than intraperitoneal administration, likely due to higher substrate 
concentrations reaching the lung [40]. Here, we assessed GLuc expression combined with 
topical administration of coelenterazine for BLI in the lung and showed that although GLuc 
expression can be detected in the lung, topical administration of the substrate leads to 
significant background photon emission in untransfected mice. Background photon emission 
in vitro has previously been reported for coelenterazine [44] and has been attributed to auto-
oxidation of the substrate, but interestingly did not appear to interfere with GLuc detection in 
various organs after systemic administration of the substrate [27,23]. It is likely that the high 
local concentration of coelenterazine in the airways achieved after topical administration 
leads to a particular enhancement of the background signal and may be reduced if the 
substrate is administered systemically. In addition, various coelenterazine analogues are 
being developed [45,46] which may be less prone to background photon emission. In 
summary, GLuc is a suitable reporter for non-viral gene transfer to the mouse lung, and 
detection of GLuc in the blood may allow us to follow gene expression over-time.  
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Confirmation of GLuc expression in the mouse lung enabled us to assess this reporter in 
sheep. Importantly, and in contrast to our experience with FLuc, robust levels of GLuc were 
detectable in lung tissue and BALF, showing, for the first time, that significant and 
reproducible levels of recombinant protein can be produced after aerosolisation of 
GL67A/pDNA complexes to the ovine lung in all treated animals. Detection of GLuc 
expression in BALF allowed us to monitor gene expression in the same sheep over time. 
Despite the prolonged half-life of GLuc in vitro the gene expression profile of pCMV-GLuc 
was transient (highest levels at day 1 after transfection, returning to baseline by day 4 after 
transfection), which follows the expected profile for the shorter-acting CMV 
promoter/enhancer. This expression profile is consistent with a comparatively short half-life 
of GLuc in vivo (approximately 20 min [26]). The protein is rapidly removed from the 
systemic circulation by excretion via the kidneys [26], but it is less clear how it is cleared 
from the lung.  
Although repeated collection of BALF is feasible the procedure requires sheep to be 
anaesthetised, whereas blood can be easily and frequently collected without the need for 
general anaesthesia. Although GL67A-mediated GLuc expression was not detectable in 
blood, transfection with concentrated PEI (cPEI) led to approximately 3-fold higher 
expression in the lung and allowed detection of GLuc in serum. We are currently developing 
a lentiviral vector for CF gene therapy [3], which is more efficient than non-viral gene 
transfer in the airway. We predict that sampling of GLuc in serum may allow us to easily 
monitor persistence of lentivirus-mediated gene expression in the airways.  
We also attempted to quantify GLuc in exhaled breath condensate (EBC), but were unable to 
detect significant increases after non-viral gene transfer. However, considering the small size 
of the protein (19.9 kD) detection of GLuc in EBC may be feasible when more efficient 
GTAs are used.  
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Conclusions 
We have shown here that GLuc is a sensitive reporter gene and is particularly useful for 
monitoring gene transfer in difficult to transfect models of the airway and lung. Specifically, 
we show that (1) GLuc is a  more sensitive reporter gene and offers significant advantages 
over the traditionally used FLuc in pre-clinical models for lung gene transfer that are difficult 
to transfect, (2) GL67A-mediated gene transfection leads to significant production of 
recombinant protein in these models, (3) promoter activity in ALI cultures mimics published 
in vivo data and these cultures may, therefore, be suitable to characterise promoter activity in 
a human ex vivo airway model and (4) detection of GLuc in large animal broncho-alveolar 
lavage fluid and serum facilitates assessment of duration of gene expression after gene 
transfer to the lungs. Importantly, this study has allowed us to validate that GL67A, which is 
currently in clinical use, can generate significant amounts of recombinant protein in fully 
differentiated human air liquid interface cultures and the ovine lung in vivo. 
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